SEC Comment Letter 0000000000-24-002947 to AC Immune SA (ACIU) (CIK 0001651625) (ACIU)
AC Immune SA (ACIU) (CIK 0001651625)
Date: March 19, 2024 · CIK: 0001651625 · Accession: 0000000000-24-002947
AI Filing Summary & Sentiment
File numbers found in text: 333-277940
Letter
United States securities and exchange commission logo March 19, 2024 Christopher Roberts Chief Financial Officer AC Immune USA, Inc. 1230 Avenue of the Americas, Ste 1634 New York, New York 10020 Re:AC Immune USA, Inc. Registration Statement on Form F-3 Filed March 14, 2024 File No. 333-277940 Dear Christopher Roberts: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Derek Dostal
Show Raw Text
United States securities and exchange commission logo
March 19, 2024
Christopher Roberts
Chief Financial Officer
AC Immune USA, Inc.
1230 Avenue of the Americas, Ste 1634
New York, New York 10020
Re:AC Immune USA, Inc.
Registration Statement on Form F-3
Filed March 14, 2024
File No. 333-277940
Dear Christopher Roberts:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Derek Dostal